Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Technologies Gets Phase I SBIR Grant for RNA Amplification Tech

NEW YORK, Oct. 7 (GenomeWeb News) - NuGen Technologies of San Carlos, Calif., said today that it has received a Phase I grant from the NIH to develop its nucleic acid amplification and detection technologies.


The company markets an Ovation RNA amplification system for gene expression, using its singler primer isothermal amplification (SPIA) technology, "a novel means of isothermal linear gene amplification," according to the grant abstract. This technology is incorporated into the company's Ribo-Spia method for isothermal linear RNA amplification, for which it has filed a patent application.


These technologies are designed to be sensitive enough to amplify up samples for small numbers of cells or single cells from tissue biopsies, laser capture microdissection, and other methods of tissue procurement. The company said it plans to use the grant to validate its technologies for this small-sample amplification.

The company did not disclose the amount of the grant, but typical SBIR Phase 1 grants are in the realm of $100,000.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.